Navigation Links
Accelitech to Open the First CyberKnife Cancer Center Within the City of Chicago
Date:2/22/2012

CHICAGO, Feb. 22, 2012  /PRNewswire/ -- Accelitech LLC, a leading developer of stereotactic radiosurgery and cancer treatment programs, is pleased to announce its newest CyberKnife cancer center, which will begin treating patients in Chicago in the summer of 2012. Developed through a partnership between Accelitech, physicians and Swedish Covenant Hospital, the new CyberKnife Cancer Institute of Chicago will provide state-of-the-art CyberKnife treatment to patients from Chicago and beyond. This will be the first CyberKnife center within the city limits and will feature the latest technology of its kind in the region.

Centrally located and conveniently accessible from both downtown and suburban locations, the new 10,000-square-foot facility, now under construction, will be located at 160 East Illinois, in the heart of Chicago. The center will open and the clinical team will begin evaluating patients for treatment beginning this spring.

"Our vision is to create the very best setting for patient care and provide the most advanced cancer treatment technology available in the market," says Adam Dickler, MD, the Medical Director for the new CyberKnife center. "More than 20 cancer care physicians have been trained to use the CyberKnife, providing new treatment options for their patients."

"With this and every project, our goal is to bring new technology to patients who need it most, so we're very excited to add our Chicago site to a rapidly growing network of Accelitech CyberKnife centers," says Kerwin Brandt, CEO of Accelitech. "With nine existing locations and many more under development, we believe we are the largest and fastest growing private developer of CyberKnife centers in the country."

About Accelitech LLC

Accelitech LLC is a leading developer of stereotactic radiosurgery and cancer treatment programs. Headquartered in Chicago, IL, Accelitech is a privately held company with extensive experience and resources in healthcare, law, finance, development, and clinical operations. Accelitech provides the funds, expertise and legal models to allow physicians and hospitals to bring new technology to market for the benefit of the patients they serve. Accelitech has sites and projects under development throughout the United States.

For additional information about Accelitech and its services, please visit accelitech.biz.

About CyberKnife Cancer Institute of Chicago by Swedish Covenant Hospital

CyberKnife is the first and only robotic radiosurgery system delivering customizable, non-surgical treatments for a broad range of tumors anywhere in the body. Only the CyberKnife system allows practitioners to non-invasively deliver high doses of radiation to tumors with extreme accuracy and intense precision, providing personalized and tailored treatments that help clinicians pursue the best clinical outcomes for patients' individual needs. The CyberKnife Cancer Institute of Chicago will open the summer of 2012 and is located at 160 East Illinois, off of Michigan Avenue in Chicago.  For more information about the center's opening, visit accelitech.biz.

Media Inquiries:
Stacey McClenathan
Stacey@beecommunications.com


'/>"/>
SOURCE Accelitech LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... -- AVACEN Medical , Inc. (AVACEN) announced that Frost ... Product Innovation Award for Its fibromyalgia pain management device. ... device market research by Frost & Sullivan,s industry experts. ... relief product, the AVACEN 100, offers a safe and effective ... ...
(Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology:
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) ... FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... Morris F. Collen, a pioneer in the field of medical informatics, this prestigious award ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
Breaking Medicine News(10 mins):